^
    Back
    Association details:
    Biomarker:JAK2 V617F
    Cancer:Acute Myelogenous Leukemia
    Drug:pracinostat (SB939) (HDAC inhibitor) +
    Vonjo (pacritinib) (JAK2 inhibitor, FLT3 inhibitor, CSF-1R inhibitor, ACVR1 inhibitor, IRAK-1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Blood Cancer J
    Title:

    The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

    Excerpt:
    Pracinostat downregulates JAK and FLT3 signaling in JAK2V617F and FLT-ITD cell lines, and shows synergy in combination with pacritinib.
    DOI:
    https://dx.doi.org/10.1038%2Fbcj.2012.14